fda drug shortages tirzepatide zepbound shortage status 2025 Compounded Semaglutide & 2025: Safe Use Guide Lilly, Novo Fight Weight Loss

We believe that medical weight loss is most successful when it is paired with clinical expertise and continuous support

Kaptanoglu AF, Oskay T

A recent puff piece in the New York Times featuring Medvi, an AI-powered telehealth startup, failed to mention a litany of legal problems the company faces, including a February warning from the FDA against Medvis use of false or misleading claims about compounded GLP-1s

However, research published in the New England Journal of Medicine showed that non-diabetic individuals with obesity experience significant weight loss on semaglutideoften exceeding 15% of body weight over 68 weeks